Study on the therapeutic effect of erlotinib on brain metastasis of lung squamous cell carcinoma

Erlotinib (Erlotinib), trade name Tarceva, is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI ), mainly used to treat patients with EGFR mutations in non-small cell lung cancer (NSCLC). Although erlotinib was initially used to treat non-small cell lung cancer, its therapeutic effect in lung cancer brain metastases, especially lung squamous cell carcinoma brain metastases, has also received widespread attention in recent years.

The main mechanism of action of Erlotinib is to inhibit the phosphorylation of EGFR and block the conduction of downstream signaling pathways, thereby inhibiting the proliferation, growth, metastasis and anti-apoptosis ability of tumor cells to achieve anti-tumor purposes. EGFR is often overexpressed or mutated in lung cancer cells, making EGFR an important target for lung cancer treatment. Erlotinib can specifically bind to EGFR and block its binding to ligands, thereby inhibiting the activity of EGFR to achieve anti-tumor effects.

Lung squamous cell carcinoma is a type of lung cancer that is highly malignant and prone to metastasis, especially brain metastasis. Brain metastasis is one of the important reasons for treatment failure in lung cancer, seriously affecting the quality of life and survival period of patients. Traditional treatments such as chemotherapy and radiotherapy have limited effectiveness in the treatment of brain metastases. Erlotinib, as a targeted therapy, provides a new option for the treatment of brain metastases from lung squamous cell carcinoma.

Clinical studies have shown that erlotinib has a certain therapeutic effect on brain metastasis of lung squamous cell carcinoma. In a retrospective study of patients with non-small cell lung cancer brain metastases who received erlotinib, the results showed that the median overall survival (OS) of patients in the erlotinib group was significantly better than that in the placebo group, which was 5.5 months and 3.4 months respectively. This shows that erlotinib has certain advantages in prolonging patient survival.

Erlotinib also showed good results in the control of brain metastases. Because it can penetrate the blood-brain barrier, erlotinib can maintain a high drug concentration in brain metastases, thereby effectively inhibiting the growth of brain metastases. This is of great significance for improving patients' quality of life and alleviating symptoms caused by brain metastasis.

Erlotinib is administered orally, usually 1 hour before eating or 2 hours after eating, once a day. For patients with non-small cell lung cancer, the recommended dose is 150 mg per day. However, in patients with brain metastases, especially those with EGFR mutations, dose adjustments may be needed on a case-by-case basis.

It is worth noting that the therapeutic effect of erlotinib is closely related to whether the patient has EGFR mutations. EGFRPatients with mutations are more sensitive to erlotinib and have better therapeutic effects. Therefore, before using erlotinib, patients usually need to be tested for EGFR gene mutations to determine whether they are suitable for this targeted therapy.

Although erlotinib has good therapeutic effects, it may also cause some adverse reactions. The most common adverse reactions include rash, diarrhea, itching, dry skin, etc. These reactions are usually mild and can be relieved with symptomatic treatment. However, a small number of patients may experience serious adverse reactions, such as interstitial pneumonia, liver damage, etc. Therefore, during the use of erlotinib, the patient's physical condition needs to be closely monitored to detect and deal with adverse reactions in a timely manner.

Erlotinib may also interact with other medications, so caution is needed when used with other medications. At the same time, erlotinib may also have adverse effects on pregnant and lactating women, so this drug should be contraindicated in these groups.